USRE49935E1 - Crystalline polymorphs of benfotiamine, process for preparation and its use thereof - Google Patents

Crystalline polymorphs of benfotiamine, process for preparation and its use thereof Download PDF

Info

Publication number
USRE49935E1
USRE49935E1 US17/666,352 US201217666352A USRE49935E US RE49935 E1 USRE49935 E1 US RE49935E1 US 201217666352 A US201217666352 A US 201217666352A US RE49935 E USRE49935 E US RE49935E
Authority
US
United States
Prior art keywords
crystalline form
crystalline
benfotiamine
ray powder
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/666,352
Other languages
English (en)
Inventor
Chunjiu Zhong
Yinhua He
Xuefeng Mei
Huan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Raising Pharmaceutical Co Ltd
Original Assignee
Shanghai Raising Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Raising Pharmaceutical Co Ltd filed Critical Shanghai Raising Pharmaceutical Co Ltd
Priority to US17/666,352 priority Critical patent/USRE49935E1/en
Application granted granted Critical
Publication of USRE49935E1 publication Critical patent/USRE49935E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention is directed to crystalline polymorphs of benfotiamine, its methods of preparation and its pharmaceutical composition in preventing and treating vitamin B1 deficiency and metabolic disorders, mental illness and disorders, diabetes complications, neurodegenerative diseases.
  • the present invention relates to the field of crystalline polymorphs of medical chemistry.
  • Benfotiamine has previously been disclosed in patent US19623064000. Its full name is S-benzoylthiamine O-monophosphate, generic name is benfotiamine, chemical name is Benzenecarbothioic acid, chemical name of formula is S-[2-[[(4-amino-2-methyl-5 pyrimidinyl)methyl]formylamino]-1-[2- (phosphonooxy)ethyl]-1 -propenyl]ester, the formula is C19H23N4O6PS and molecular weight is 466.45. It has the following chemical structural:
  • a substance with the same chemical composition may crystallize with two or more different spatial lattice arrangements. This phenomenon is called polymorphism.
  • the polymorphic behavior of drugs can be of crucial importance in pharmacy and pharmacology, which takes tremendous impacts on drug quality. Varied crystalline forms may differ from each other with respect to one or more physical properties, such as crystal shape, melting point, hardness, solubility and dissociation, state stability and compaction behavior.
  • the differences in physical properties exhibited by polymorphs affect pharmaceutical parameters such as storage stability, bioavailability and efficacy. Therefore, new drug R&D should give more attention to the research on drug polymorphism and crystalline control.
  • Benfotiamine is the fat-soluble derivative of vitamin B1, which greatly improve low-bioavailability of water-soluble vitamin B1, elevating thiamine level in blood and tissues, so as to its therapeutic efficacy.
  • Indications for benfotiamine (1) prevention and treatment of vitamin B1 deficiency; (2) additional supplement for vitamin B1 inadequacy from diet malabsorption (due to fatigue, hyperthyroidism, pregnancy, lactation, intensive physical labor); (3) wasnicke's encephalopathy; (4) beriberi; (5) any other diseases result from vitamin B1 deficiency and disorders, such as neuropathy, muscle pains, joint pains, peripheral polyneuritis, peripheral nerve paralysis, myocardial metabolic disorder, constipation and other gastrointestinal dysfunction. Benfotiamine has been industrialized and distributed in America, Japan, Europe and other countries as vitamin B1 supplements.
  • AD Alzheimer's disease
  • AD is an aging-related progressive neurodegenerative disease, of which the most common early symptoms are cognitive and behavior impairments.
  • the incidence of AD increases dramatically with the ageing of the society. There were 6 million people in China with AD.
  • AD is predicted to affect 30 million individuals globally by 2050.
  • the death rates of cancers, stroke, and cardiovascular diseases as the leading cause of the death decrease according to the progress of medical therapy, but AD incidence is still roaring in large percentage. Additionally, due to long-lasting and high impairment rate of AD, it has turned into one of the most severe life-threatening diseases in 21 st century.
  • the medical treatment costs of AD have been calculated to 604 billion US dollars in 2010, which account for almost 1% of global GDP.
  • acetylcholinesterase inhibitors As of nowadays, including China and America, two categories of drugs have been approved for AD treatment: acetylcholinesterase inhibitors and N-methyl-D-asparate receptor antagonist. However, no medication has been clearly shown to delay or halt the progression of the disease. Benfotiamine has been proved to reduce celebral ⁇ -amyloid (A ⁇ ) deposition and tau hyperphosphorylation, subsequently alleviating the AD pathologic occurrence.
  • a ⁇ ⁇ -amyloid
  • Benfotiamine is mainly administered by tablets and powders, but rarely disclosing the exact crystalline forms involved in these drugs. No systematic researches have been carried out in crystalline polymorphs of benfotiamine.
  • the present invention is related to a systematic insight of crystalline polymorphs of benfotiamine. The characters of diverse crystalline forms of benfotiamine and their potential for new drug development are disclosed.
  • JP 37-13484B (Sankyo company, Ltd.)(Oct. 9, 1962), discloses a colorless needle-like purified benfotiamine crystal, with a melting point of about 160° C.-162° C.
  • D2 JP 37-16042B (Sankyo company Ltd.)(Aug. 10, 1962), discloses three benfotiamine crystalline forms, comprising crystalline form ⁇ (C19H23O6N4SP.2H2O, melting point about 165° C.), crystalline form ⁇ (C19H23O6N4SP.15H2O, melting point about 150° C.), and crystalline form ⁇ (C19H23O6N4SP, melting point about 195° C.).
  • D3 B1 ( 6 ) S-Benzoylthiamine O-Monophosphate , , 1962 14 64-66 , ISSN: 0371-8670, discloses benfotiamine crystalline form ⁇ and its hydrates.
  • D2 discloses a method for making benfotiamine crystalline form ⁇ by keeping temperature 0-5° C. and adjusting pH to 4, which is theoretically identical to the process of preparing benfotiamine crystalline form disclosed in example 1 of D1.
  • benfotiamine crystalline form in D1 and benfotiamine crystalline form ⁇ in D2 are the same through their melting point.
  • the hydrates crystalline forms of benfotiamine disclosed in D3 are equivalent to crystalline form ⁇ and ⁇ in D2.
  • D2 and D3 disclose a benfotiamine crystalline form ⁇ without crystal water, of which the melting point is 195° C.
  • the present invention is directed to crystalline polymorphs of benfotiamine.
  • the present invention discloses a benfotiamine crystal, wherein the form can be any one of crystal forms below:
  • Crystalline form A characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ ) values) of about 11.317°, 16.377°, 17.874°, 18.543°, 19.313°, 20.850°, 21.295°, 24.858°, 25.142°.
  • Crystalline form B characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 11.459°, 16.883°, 18.644°, 20.669°, 21.295°, 22.773°, 24.817°, 25.728°, 27.327°.
  • Crystalline form C characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 10.811°, 11.338°, 14.516°, 16.984°, 18.684°, 19.352°, 20.809°, 21.336°, 22.854°.
  • Crystalline form D characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 10.690°, 11.033°, 14.414°, 15.365°, 15.952°, 18.725°, 24.350°, 25.081°, 25.323°.
  • Crystalline form E characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 9.334°, 11.863°, 12.633°, 13.260°, 13.484°, 14.395°, 15.588°, 17.206°, 18.015°, 18.948°, 19.635°, 21.276°, 22.025°, 23.703°, 24.352°, 24.938°, 26.314°, 27.023°.
  • crystalline form A is characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 8.869°, 11.317°, 13.665°, 14.839°, 16.377°, 17.874°, 18.543°, 19.313°, 20.850°, 21.295°, 22.853°, 24.858°, 25.142°, 27.631°, 28.864°.
  • crystalline form A is fundamentally consistent with FIG. 1 a in an X-ray powder diffraction pattern.
  • crystalline form A is fundamentally consistent with FIG. 1 b, 1 c, 1 d in differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy respectively.
  • DSC differential scanning calorimetry
  • IR infrared spectroscopy
  • raman spectroscopy respectively.
  • crystalline form B is characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 11.459°, 15.122°, 16.883°, 17.693°, 18.644°, 19.271°, 20.669°, 21.295°, 22.773°, 24.817°, 25.728°, 27.327°, 29.128°.
  • crystalline form B is fundamentally consistent with FIG. 2 a in an X-ray powder diffraction pattern.
  • crystalline form B is fundamentally consistent with FIG. 2 b, 2 c, 2 d in differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy respectively.
  • DSC differential scanning calorimetry
  • IR infrared spectroscopy
  • raman spectroscopy respectively.
  • crystalline form C is characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 8.889°, 10.811°, 11.338°, 13.908°, 14.516°, 15.223°, 16.984°, 17.793°, 18.684°, 19.352°, 20.809°, 21.336°, 22.854°, 23.276°, 25.424°, 28.561°, 33.054°.
  • crystalline form C is fundamentally consistent with FIG. 3 a in an X-ray powder diffraction pattern.
  • crystalline form C is fundamentally consistent with FIG. 3 b, 3 c, 3 d in differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy respectively.
  • crystalline form D is characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 10.690°, 11.033°, 14.414°, 15.365°, 15.952°, 18.725°, 19.310°, 19.797°, 21.032°, 21.256°, 24.350°, 25.081°, 25.323°, 28.318°.
  • crystalline form D is fundamentally consistent with FIG. 4 a in an X-ray powder diffraction pattern.
  • crystalline form D is fundamentally consistent with FIG. 4 b, 4 c, 4 d in differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy respectively.
  • crystalline form E is characterized by an X-ray powder diffraction pattern with significant peaks at diffraction angles (2 ⁇ values) of about 9.334°, 11.863°, 12.633°, 13.260°, 13.484°, 14.395°, 15.588°, 17.206°, 18.015°, 18.948°, 19.635°, 20.042°, 21.276°, 22.025°, 23.703°, 24.352°, 24.938°, 26.314°, 27.023°, 30.828°, 32.083°.
  • crystalline form E is fundamentally consistent with FIG. 5 a in an X-ray powder diffraction pattern.
  • crystalline form E is fundamentally consistent with FIG. 5 b, 5 c, 5 d in differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy respectively.
  • the present invention is directed to the process of preparing the crystalline of benfotiamine of the following methods:
  • Method 1 Crystalline form E of benfotiamine was suspended in an organic solvent, followed by stirring until complete dissolving. Then, the crystalline form A benfotiamine was obtained by evaporated slowly under 25° C.; or
  • Method 2 Crystalline form E of benfotiamine was suspended in an organic solvent mixture of methanol and dichloromethane (volume ratio 1:3), followed by stirring until complete dissolving. Other poor organic solvent was then added slowly add while being stirred. Then, the crystalline form A was obtained by filtered and evaporated in the air; or Method 3: Crystalline form E of benfotiamine was suspended in an organic solvent, followed by stirring in a hybrid oven for at least 24 h. Then, the crystalline form B was obtained by filtered and evaporated in the air; or Method 4: Crystalline form E of benfotiamine was suspended in an organic solvent and the mixture was heated to 60° C. while being stirred until complete dissolving.
  • Method 5 Crystalline form E of benfotiamine was suspended in an organic solvent, followed by stirring using a stirrer for at least 24 h. Then, the crystalline form D was obtained by filtered and evaporated in the air; or
  • the organic solvent includes at least one member selected from the group consisting of ketones, ethers, aliphatic hydrocarbons, aromatic hydrocarbons, esters, nitriles, alcohols, halogenated hydrocarbons, and mixtures thereof, which dissolves the benfotiamine and does not ruin its structure.
  • the organic solvent includes at least one member selected from the group consisting of methanol, ethanol, isopropanol, pentanol, acetone, 2-butanone, tetrahydrofuran, nitromethane, acetonitrile, chloroform, dichloromethane, methyl tert-butyl ether and mixtures thereof.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of crystalline benfotiamine and at least any one form pharmaceutically acceptable excipients according to claims 1 to 16 which contain pharmaceutically effective doses.
  • pharmaceutically acceptable excipients comprise at least one member selected from fillers, disintegrants, binders, lubricants and mixtures thereof.
  • fillers comprise at least one member selected from starch, lactose, crystalline cellulose, dextrin, mannitol, oxidase, calcium sulfate and mixtures thereof.
  • disintegrants comprise at least one member selected from carboxymethylcellulose and its salt, crosslinked carboxymethylcellulose and its salt, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropylcellulose and mixtures thereof.
  • binders comprise at least one member selected from polyvinylpyrrolidone, hydroxypropyl methyl cellulose, starch slurry and mixtures thereof.
  • lubricants comprise at least one member selected from magnesium stearate, calcium stearate and mixtures thereof.
  • the crystalline polymorphs of benfotiamine of the present invention are useful as they act directly on treatment of Vitamin B1 deficiency, metabolic disorders, mental illness and disorders, diabetes complications, neurodegerative diseases.
  • neurodegerative diseases include Alzheimer's disease, vascular dementia and mental retard.
  • the present invention is a process for preparing and transforming diverse crystalline forms of benfotiamine through different synthesis routes and varied solvents and combinations.
  • the crystalline polymorphs of the present invention are basically pure.
  • the present invention not only provides new crystalline forms of benfotiamine, but also provides its new solvates, especially hydrates.
  • the present invention discloses five benfotiamine crystalline forms, wherein crystalline form A is free of crystal water, crystalline form B contains one crystal water, crystalline form C is a solvate, crystalline form D has half of one crystal water, and crystalline form E has one crystal water. All the crystalline forms mentioned in the present invention are different from the crystalline form in D1 (JP 37-13484B), crystalline forms ⁇ , ⁇ in D2 (JP 037-16042B) and the hydrates crystalline forms in D3 ( ). D2 and D3 disclose a benfotiamine crystalline form ⁇ free of crystal water, of which the melting point is 195° C.
  • the melting point of crystalline form A in present invention is 205° C., which is notably separate from crystalline form ⁇ in accordance with common knowledge of skilled persons in this field by 10 degrees gap on melting point. Therefore, crystalline form A in present invention and crystalline form ⁇ mentioned in D2 and D3 shall not be the same crystalline form.
  • FIG. 1 a is a characteristic X-ray Powder Diffraction (XRPD) pattern for crystalline form A of benfotiamine.
  • FIG. 1 b is a characteristic Differential Scanning calorimetry (DSC) thermogram for crystalline form A of benfotiamine.
  • DSC Differential Scanning calorimetry
  • FIG. 1 c is a characteristic infrared spectroscopy (IR) pattern for crystalline form A of benfotiamine.
  • FIG. 1 d is a characteristic raman spectroscopy pattern for crystalline form A of benfotiamine.
  • FIG. 2 a is a characteristic X-ray Powder Diffraction (XRPD) pattern for crystalline form B of benfotiamine.
  • FIG. 2 b is a characteristic Differential Scanning calorimetry (DSC) thermogram for crystalline form B of benfotiamine.
  • DSC Differential Scanning calorimetry
  • FIG. 2 c is a characteristic infrared spectroscopy (IR) pattern for crystalline form B of benfotiamine.
  • FIG. 2 d is a characteristic raman spectroscopy pattern for crystalline form B of benfotiamine.
  • FIG. 3 a is a characteristic X-ray Powder Diffraction (XRPD) pattern for crystalline form C of benfotiamine.
  • FIG. 3 b is a characteristic Differential Scanning calorimetry (DSC) thermogram for crystalline form C of benfotiamine.
  • DSC Differential Scanning calorimetry
  • FIG. 3 c is a characteristic infrared spectroscopy (IR) pattern for crystalline form C of benfotiamine.
  • FIG. 3 d is a characteristic raman spectroscopy pattern for crystalline form C of benfotiamine.
  • FIG. 4 a is a characteristic X-ray Powder Diffraction (XRPD) pattern for crystalline form D of benfotiamine.
  • FIG. 4 b is a characteristic Differential Scanning calorimetry (DSC) thermogram for crystalline form D of benfotiamine.
  • DSC Differential Scanning calorimetry
  • FIG. 4 c is a characteristic infrared spectroscopy (IR) pattern for crystalline form D of benfotiamine.
  • FIG. 4 d is a characteristic raman spectroscopy pattern for crystalline form D of benfotiamine.
  • FIG. 5 a is a characteristic X-ray Powder Diffraction (XRPD) pattern for crystalline form E of benfotiamine.
  • FIG. 5 b is a characteristic Differential Scanning calorimetry (DSC) thermogram for crystalline form E of benfotiamine.
  • DSC Differential Scanning calorimetry
  • FIG. 5 c is a characteristic infrared spectroscopy (IR) pattern for crystalline form E of benfotiamine.
  • FIG. 5 d is a characteristic raman spectroscopy pattern for crystalline form E of benfotiamine.
  • FIG. 6 is an overlapping pattern of FIG. 1 a, 2 a, 3 a, 4 a , and 5 a.
  • FIG. 7 is an overlapping pattern of FIG. 1 b, 2 b, 3 b, 4 b , and 5 b.
  • X-ray powder diffraction (XRPD) patterns of the polymorphs are measured on a Bruker D2 phaser X-ray powder diffractometer using Cu-Ka radiation at room temperature.
  • the tube voltage and amperage ware set to 40 kV and 40 mA, respectively.
  • a theta-two theta continuous scan at 0.1 sec/step from 3° to 40° 2 ⁇ is used.
  • the pattern of crystalline is characteristic in X-ray powder diffraction pattern.
  • the band especially in low angle, can be slightly changed in the relative intensity depending on crystallization condition, particle size, relative concentration of mixture and other measurement condition. Therefore, the relative intensity of diffraction angle 2 ⁇ of the crystalline form is not characteristic.
  • the identification of crystalline form should be determined with the reference to the peak positions, but not their relative intensity. Additionally, the identification of crystalline form should not depend on one single peak, but comprehensive analysis of specific dI/II system. Moreover, during the identification of mixture, some deficiency of peak can occur due to decline in sample concentration. Therefore, it is not necessary to find safe bands appeared in highly pure samples. Even a single band may identify the crystalline form.
  • DSC Differential Scanning calorimetry
  • IR Infrared spectroscopy
  • Raman spectroscopy pattern of the polymorphs are measured on DXR (Thermo Scientific, USA) under room temperature, scanning at 3500-50 cm ⁇ 1 .
  • Step1 In a glass vial, 135 g of phosphoric acid (85%) was mixed with 155 g of phosphorus pentoxide, followed by stirring until complete dissolving. Then, 100 g of thiamine hydrochloride was added to the mixture, followed by stirring until no gas was observed. Hydrochloric acid was further added dropwise until no gas was observed.
  • Step2 The resultant mixture was added to acetone. Precipitated crystals were collected by filtration.
  • the resultant thiamine monophosphate was dissolved in water, followed by adding 30% of sodium hydroxide to pH 12. Benzoyl chloride was then added slowly to the mixture, followed by stirring at room temperature for 3 hours. Precipitated crystals were collected by filtration.
  • Step3 Crystalline form E of benfotiamine was obtained by washing the precipitated crystals formed in step2 with ethanol.
  • the crystalline form E of benfotiamine was measured by differential scanning calorimetry (DSC), infrared spectroscopy (IR) and raman spectroscopy, respectively, as shown in FIG. 5 b, 5 c, 5 d .
  • the crystalline form A of benfotiamine was measured by io differential scanning calorimetry (DSC), infrared spectroscopy (IR) and raman spectroscopy, respectively, as shown in FIG. 1 b, 1 c, 1 d .
  • Crystalline form A of benfotiamine was obtained in the same manner as in Example 3, except the poor solvent was isopropanol.
  • the X-ray power diffraction pattern showed the compound was crystalline form A, as described in table 2.
  • Crystalline form A of benfotiamine was obtained in the same manner as in Example 3, except the poor solvent was pentanol.
  • the X-ray power diffraction pattern showed the compound was crystalline form A, as described in table 2.
  • Crystalline form A of benfotiamine was obtained in the same manner as in Example 3, except the poor solvent was 2-butanone.
  • the X-ray power diffraction pattern showed the compound was crystalline form A, as described in table 2.
  • Crystalline form A of benfotiamine was obtained in the same manner as in Example 3, except the poor solvent was methylbenzene.
  • the X-ray power diffraction pattern showed the compound was crystalline form A, as described in table 2.
  • the crystalline form B of benfotiamine was measured by differential scanning calorimetry (DSC), infrared spectroscopy (IR) and raman spectroscopy, respectively, as shown in FIG. 2 b, 2 c, 2 d .
  • Crystalline form B of benfotiamine was obtained in the same manner as in Example 8, except the organic solvent was isopropanol.
  • the X-ray power diffraction pattern showed the compound was crystalline form B, as described in table 3.
  • the crystalline form C of benfotiamine was measured by differential scanning calorimetry (DSC), infrared spectroscopy (IR) and raman spectroscopy, respectively, as shown in FIG. 3 b, 3 c, 3 d .
  • Crystalline form C of benfotiamine was obtained in the same manner as in Example 10, except the organic solvent was a mixture of methanol and dichloromethane (volume ratio 1:2). The X-ray power diffraction pattern showed the compound was crystalline form C, as described in table 4.
  • Crystalline form C of benfotiamine was obtained in the same manner as in Example 10, except the organic solvent was a mixture of methanol and chloroform (volume ratio 1:2). The X-ray power diffraction pattern showed the compound was crystalline form C, as described in table 4.
  • the crystalline form D of benfotiamine was measured by differential scanning calorimetry (DSC), infrared spectroscopy (IR) and raman spectroscopy, respectively, as shown in FIG. 4 b, 4 c, 4 d .
  • Crystalline form D of benfotiamine was obtained in the same manner as in Example 13, except the organic solvent was pentanol.
  • the X-ray power diffraction pattern showed the compound was crystalline form D, as described in table 5.
  • Crystalline form D of benfotiamine was obtained in the same manner as in Example 13, except the organic solvent was acetone.
  • the X-ray power diffraction pattern showed the compound was crystalline form D, as described in table 5.
  • Crystalline form D of benfotiamine was obtained in the same manner as in Example 13, except the organic solvent was 2-butanone.
  • the X-ray power diffraction pattern showed the compound was crystalline form D, as described in table 5.
  • Crystalline form D of benfotiamine was obtained in the same manner as in Example 13, except the organic solvent was tetrahydrofuran.
  • the X-ray power diffraction pattern showed the compound was crystalline form D, as described in table 5.
  • Crystalline form D of benfotiamine was obtained in the same manner as in Example 13, except the organic solvent was nitromethane.
  • the X-ray power diffraction pattern showed the compound was crystalline form D, as described in table 5.
  • Dynamic vapor sorption analysis was used for measurement of the hygroscopicity of crystalline form A, C, D, and E under the scope of relative humidity (RH) from 5% to 95%. It indicated that hygroscopicity of the four crystalline forms was all under 2.0%, wherein the crystalline form E has the lowest hygroscopicity, and the crystalline form D has the highest hygroscopicity.
  • the crystals of the present invention preferably contains 90% or more of a crystalline substance, more preferably 95% or more, further preferably 96% or more, more further preferably 97% or more, especially preferably 98% or more, most preferably 99% or more of a crystalline substance, which used in X-ray powder diffraction (XRPD), raman spectroscopy, infrared spectroscopy (IR).
  • XRPD X-ray powder diffraction
  • IR infrared spectroscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
US17/666,352 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof Active 2033-01-09 USRE49935E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/666,352 USRE49935E1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210395556.6 2012-10-17
CN201210395556.6A CN103113405B (zh) 2012-10-17 2012-10-17 苯磷硫胺多晶型体、制备方法及其应用
PCT/CN2012/083898 WO2014059702A1 (zh) 2012-10-17 2012-10-31 苯磷硫胺多晶型体、制备方法及其应用
US14/432,079 US9718846B1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof
US17/666,352 USRE49935E1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof

Publications (1)

Publication Number Publication Date
USRE49935E1 true USRE49935E1 (en) 2024-04-23

Family

ID=48411826

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/432,079 Ceased US9718846B1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof
US17/666,352 Active 2033-01-09 USRE49935E1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/432,079 Ceased US9718846B1 (en) 2012-10-17 2012-10-31 Crystalline polymorphs of benfotiamine, process for preparation and its use thereof

Country Status (8)

Country Link
US (2) US9718846B1 (de)
EP (1) EP2918593B1 (de)
JP (1) JP6392766B2 (de)
CN (1) CN103113405B (de)
ES (1) ES2649412T3 (de)
PL (1) PL2918593T3 (de)
PT (1) PT2918593T (de)
WO (1) WO2014059702A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724374B (zh) * 2014-01-08 2016-01-27 珠海金鸿药业股份有限公司 一种苯磷硫胺化合物及制备方法及其含有该化合物的药物组合物
CN111638234B (zh) * 2014-08-13 2024-09-03 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN112933101A (zh) * 2017-06-26 2021-06-11 上海日馨生物科技有限公司 苯磷硫胺衍生物、制备方法及其药物组合物
WO2020067832A1 (ko) * 2018-09-28 2020-04-02 경북대학교 산학협력단 티아민 유도체를 포함하는 고코르티솔증 예방 또는 치료용 조성물
CN111233925B (zh) * 2018-11-28 2021-03-26 上海日馨生物科技有限公司 硫胺类化合物、制备方法及其药物组合物
US10947258B1 (en) 2019-08-23 2021-03-16 Shanghai Rixin Biotechnology Co., Ltd. Benfotiamine derivatives, method for preparing the same and pharmaceutical composition comprising the same
CN118234735A (zh) * 2021-11-22 2024-06-21 上海日馨医药科技股份有限公司 苯磷硫胺衍生物的固体形式及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB896089A (en) 1959-04-14 1962-05-09 Sankyo Kabushiki Kaisha Derivatives of thiamine and their production
DE1130811B (de) 1959-04-14 1962-06-07 Sankyo Kabushiki Kaisha Verfahren zur Herstellung eines Acylierungsproduktes von Vitamin-B-orthophosphorsaeureester und Salzen davon
US3064000A (en) 1959-04-14 1962-11-13 Sankyo Kabushiki Kaisha S-benzoylthiamine o-monophosphate and a process for preparing the same
JPH1053526A (ja) 1996-06-03 1998-02-24 Takeda Chem Ind Ltd 医薬組成物
JP2006008576A (ja) 2004-06-25 2006-01-12 Kosei Tanaka ヘキサミン生合成経路活性化抑制剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600101A (es) * 2005-03-08 2006-11-09 Formas cristalinas de 2-(3-fluoro-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
PT2091910E (pt) * 2006-12-06 2014-11-18 Conatus Pharmaceuticals Inc Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico
SI2124933T1 (sl) * 2007-01-22 2012-12-31 Pfizer Products Inc. Tosilatna sol terapevtske spojine in farmacevtski sestavi tega

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB896089A (en) 1959-04-14 1962-05-09 Sankyo Kabushiki Kaisha Derivatives of thiamine and their production
DE1130811B (de) 1959-04-14 1962-06-07 Sankyo Kabushiki Kaisha Verfahren zur Herstellung eines Acylierungsproduktes von Vitamin-B-orthophosphorsaeureester und Salzen davon
US3064000A (en) 1959-04-14 1962-11-13 Sankyo Kabushiki Kaisha S-benzoylthiamine o-monophosphate and a process for preparing the same
JPH1053526A (ja) 1996-06-03 1998-02-24 Takeda Chem Ind Ltd 医薬組成物
JP2006008576A (ja) 2004-06-25 2006-01-12 Kosei Tanaka ヘキサミン生合成経路活性化抑制剤

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Asai et al., "A synthesis method of S-Benzoylthiamine O-Monophosphate", Takamine Kenkyujo Nenpo, 1961, vol. 13, pp. 45-47.
Caira, "Crystalline Polymorphism of Organic Compounds" Topics in Current Chemistry, 1998, No. 198, pp. 163-208.
Chinese Patent Application No. 201210395556.6: First Office Action dated Nov. 2, 2014, 12 pages.
English Translation of I. Akira et. al., 82 Yakugaku Zasshi, 883-888 (1962). *
European Patent Application No. 12886858.5 — 1451/2918593: Search Report dated Jul. 22, 2016, 7 pages.
I. Akira et. al., 82 Yakugaku Zasshi, 883-888 (1962). *
International Patent Application No. PCT/CN2012/083898: International Search Report dated Jul. 25, 2013, 20 pages.
Ito et al., "Research on Vitamin B1 Phosphate ester (No. 6),the crystalline form and formation of S-Benzoylthiamine O-Monophosphate", Takamine Kenkyusho Nenpo, 1962, vol. 14, pp. 64-66.
Ito et al., "Studies on thiamine phosphates, (ii) physicochemical properties of s-benzoylthiamine o-monophosphate", the Vitamin Society of Japan, Takamine Laboratory, 1961, 9 pages.
Ito, "Synthesis, properties and application of sodium Acylthiosulfate (No. 4), Synthesis of SAcylthiamine Derivatives", Journal of the Pharmaceutical Society of Japan, 1962, vol. 82, No. 6, pp. 883-888.
Japanese Patent Application No. 2015-537105: Notification of Reasons for Refusal dated Jul. 19, 2016, 8 pages.
Kanaka, "Concise explanation of the relevance of Handbook of organic compound crystal production", Kodansha Co., Ltd., 2008, pp. 17-23, 37-40, 45-51, 57-65.
Kojima, "Study on High Efficiency Screening of Crystal in Drug R & D", Pharmaceutics, Sep. 1, 2008, vol. 68, No. 5, pp. 344-349.
Solid State Characterization of Pharmaceuticals 427-450 (R.A. Storey et al., eds., 2011). *
Takada , "API form screening and selection in drug discovery stage", Pharm Stage, Jan. 15, 2007, vol. 6, No. 10, pp. 20-25.

Also Published As

Publication number Publication date
PL2918593T3 (pl) 2018-03-30
JP2015534953A (ja) 2015-12-07
PT2918593T (pt) 2018-01-11
WO2014059702A1 (zh) 2014-04-24
CN103113405A (zh) 2013-05-22
CN103113405B (zh) 2016-03-02
EP2918593A4 (de) 2016-08-24
EP2918593B1 (de) 2017-10-18
US9718846B1 (en) 2017-08-01
EP2918593A1 (de) 2015-09-16
JP6392766B2 (ja) 2018-09-19
ES2649412T3 (es) 2018-01-11

Similar Documents

Publication Publication Date Title
USRE49935E1 (en) Crystalline polymorphs of benfotiamine, process for preparation and its use thereof
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
US20210317085A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
US9221815B2 (en) Solid state form of vemurafenib choline salt
US8486927B2 (en) Crystalline forms of lamotrigine
US11103512B2 (en) Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
TW202404604A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
TWI728404B (zh) 一種1,2,4-三-3-胺類衍生物的晶型及製備方法
US20240254122A1 (en) Process for preparation of sotorasib and solid state form thereof
US11208382B2 (en) Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
US9694004B2 (en) Crystal form
US9181243B2 (en) Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof
US20220153744A1 (en) Solid state forms of acalabrutinib
US20070032506A1 (en) Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
US20220009929A1 (en) Polymorphic forms of ibrutinib
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
US8710078B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
US20230271967A1 (en) Solid state forms of fezolinetant and salts thereof
WO2024069574A1 (en) Solid state forms of denifanstat
WO2024062344A1 (en) Solid state forms of mesdopetam and salts therof
JP2015127325A (ja) 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY